THU0111 Ra Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy

Abstract

BackgroundMethotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of tolerability or efficacy.1,2 Subcutaneous (SC) MTX...